Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Valeria Magarotto, S. Bringhen, Massimo Offidani, Giulia Benevolo, F. Patriarca, Roberto Mina, Antonietta Pia Falcone, Lorenzo De Paoli, Giuseppe Pietrantuono, Silvia Gentili, Caterina Musolino, Nicola Giuliani, Annalisa Bernardini, C. Conticello, Stefano Pulini, G. Ciccone, Vladimír Maisnar, M. Ruggeri, R. Zambello, Tommasina GuglielmelliAntonio Ledda, A. M. Liberati, Vittorio Montefusco, Roman Hajek, M. Boccadoro, A. Palumbo

Research output: Contribution to journalArticle

Abstract

Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus lowdose dexamethasone (Rd). The primary end point was progression-free survival (PFS) in triplet (MPR and CPR) vs doublet (Rd) lenalidomide-containing regimens. After a median follow-up of 39 months, the medianPFSwas22 months for the triplet combinations and 21 months for the doublet (P =.284). The median overall survival (OS) was not reached in either arms, and the 4-year OS was 67% for the triplet and 58% for the doublet arms (P =.709). By considering the 3 treatment arms separately, no difference in outcome was detected among MPR, CPR, and Rd. The most common grade ≥3 toxicity was neutropenia: 64% in MPR, 29% in CPR, and 25% in Rd patients (P

Original languageEnglish
Pages (from-to)1102-1108
Number of pages7
JournalBlood
Volume127
Issue number9
DOIs
Publication statusPublished - Mar 3 2016

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

Cite this